Akebia Therapeutics (AKBA) Depreciation & Amortization (CF) (2013 - 2026)
Akebia Therapeutics (AKBA) reported Depreciation & Amortization (CF) of $328000.0 for Q1 2026, up 4.46% year-over-year from $314000.0 in Q1 2025, and up 2.18% quarter-over-quarter from $321000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $328000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $328000.0, up 4.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 9.14% YoY), and the FY2025 annual result was $1.3 million, down 13.2% from the prior year.
- Depreciation & Amortization (CF) rose to $328000.0 in Q1 2026 per AKBA's latest filing, from $321000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $417000.0 in Q1 2022 and troughed at $314000.0 in Q1 2025.
- A 5-year average of $370470.6 and a median of $394000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) fell 21.0% in 2025, then climbed 4.46% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $408000.0 in 2022, then dropped by 3.43% to $394000.0 in 2023, then slipped by 14.97% to $335000.0 in 2024, then dropped by 4.18% to $321000.0 in 2025, then increased by 2.18% to $328000.0 in 2026.
- Business Quant data shows AKBA's Depreciation & Amortization (CF) at $328000.0 in Q1 2026, $321000.0 in Q4 2025, and $318000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | 328,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 328,000.00 |
| Mar 31, 2026 | 328,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Jun 30, 2025 | 316,000.00 |
| Jun 30, 2025 | 316,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Dec 31, 2024 | 335,000.00 |
| Dec 31, 2024 | 335,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 364,000.00 |
| Mar 31, 2024 | 364,000.00 |
| Dec 31, 2023 | 394,000.00 |
| Dec 31, 2023 | 394,000.00 |